Cytek Biosciences (CTKB) Current Assets (2020 - 2026)

Cytek Biosciences' Current Assets history runs 7 years deep, the most recent figure standing at $379.3 million for Q1 2026.

• Quarterly Current Assets changed 0.32% year-over-year to $379.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $379.3 million (changed 0.32% YoY) and the FY2025 annual result came in at $392.0 million, down 1.12% from the prior year.
• Current Assets was $379.3 million for Q1 2026 at Cytek Biosciences, down from $392.0 million in the prior quarter.
• Across five years, Current Assets topped out at $454.0 million in Q4 2022 and bottomed at $379.3 million in Q1 2026.
• A 5-year average of $407.5 million and a median of $392.1 million in 2023 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets jumped 104.33% — and 2023, when it decreased 13.65%.
• Cytek Biosciences' Current Assets stood at $454.0 million in 2022, then slipped by 13.65% to $392.1 million in 2023, then advanced by 1.12% to $396.4 million in 2024, then dropped by 1.12% to $392.0 million in 2025, then fell by 3.24% to $379.3 million in 2026.
• Business Quant data shows CTKB's Current Assets at $379.3 million in Q1 2026, $392.0 million in Q4 2025, and $388.5 million in Q3 2025.